LIXTE BIOTECHNOLOGY HOLDINGS INC

For the period ended Dec 31, 2023. Filed Mar 19, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 19, 2024

NMAD$3.78+5.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets – December 31, 2023 and 2022

	December 31,
	2023	2022
ASSETS
Current assets:
Cash	$4,203,488	$5,353,392
Advances on research and development contract services	78,016	147,017
Prepaid insurance	17,116	49,224
Other prepaid expenses	10,000	11,350
Total current assets	4,308,620	5,560,983
Total assets	$4,308,620	$5,560,983
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses, including $36,250 and $46,982 to related parties at December 31, 2023 and 2022, respectively	$156,758	$230,734
Research and development contract liabilities	157,100	165,022
Total current liabilities	313,858	395,756
Commitments and contingencies	-
Stockholders’ equity:
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 72,917 shares	3,500,000	3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 2,249,290 shares and 1,664,706 shares at December 31, 2023 and 2022, respectively	225	166
Additional paid-in capital	48,976,265	45,059,760
Accumulated deficit	(48,481,728)	(43,394,699)
Total stockholders’ equity	3,994,762	5,165,227
Total liabilities and stockholders’ equity	$4,308,620	$5,560,983

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.